|1.||Sredni, Benjamin: 26 articles (03/2015 - 07/2002)|
|2.||Albeck, Michael: 17 articles (03/2015 - 07/2002)|
|3.||Kalechman, Yona: 9 articles (03/2015 - 07/2002)|
|4.||Sredni, B: 9 articles (06/2012 - 04/2000)|
|5.||Albeck, M: 7 articles (06/2012 - 04/2000)|
|6.||Okun, Eitan: 5 articles (06/2014 - 01/2007)|
|7.||Gafter, Uzi: 5 articles (01/2014 - 07/2002)|
|8.||Longo, Dan L: 4 articles (03/2015 - 03/2004)|
|9.||Hayun, Michal: 3 articles (01/2013 - 11/2006)|
|10.||Freidkin, Ilya: 3 articles (06/2004 - 03/2003)|
|1.||Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental)
08/15/2014 - "We further demonstrated that AS101 was effective in amelioration of experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis. "
08/15/2014 - "The immunomodulator AS101 suppresses production of inflammatory cytokines and ameliorates the pathogenesis of experimental autoimmune encephalomyelitis."
06/01/2014 - "Tellurium compound AS101 ameliorates experimental autoimmune encephalomyelitis by VLA-4 inhibition and suppression of monocyte and T cell infiltration into the CNS."
03/01/1991 - "AS101 was found to have a synergistic effect with CYP in the treatment of tumor-bearing mice, suggesting that the combination of these two modalities provides a more effective treatment of their tumors. "
03/01/2003 - "In vivo animal studies using AS101, currently undergoing phase II clinical trials on cancer patients, are warranted to determine its potential in the management of glomerular diseases associated with mesangial cell proliferation."
09/15/1997 - "We suggest that treatment with a nontoxic immunomodulator such as AS101, previously used in phase II trials on cancer patients, may be an effective therapeutic approach for controlling SLE."
03/15/1997 - "The ability of AS-101 to potentiate the effects of chemotherapeutic drugs and augment cytokine production in vivo has led to clinical trials on AS-101 which are currently being carried out in cancer patients. "
09/18/1996 - "The aim of this study was to evaluate the ability of AS101 to modulate TH1 and TH2 responses in tumor-bearing mice and in patients with advanced cancer. "
08/01/2007 - "In this study, we show that AS101 improves functional outcome and reduces brain damage in a mouse model of focal ischemic stroke. "
08/01/2007 - "As AS101 has an excellent safety profile in humans, our pre-clinical data suggest a potential therapeutic benefit of AS101 in patients suffering from stroke and other neurodegenerative conditions."
08/01/2007 - "Both pre-stroke and post-stroke intraperitoneal treatments with AS101 reduced infarct size and edema and improved the neurological function of the animals. "
08/01/2007 - "Moreover, AS101 treatment reduced glutamate-induced intracellular calcium elevation, a major contributor to neuronal death in stroke. "
|1.||ammonium trichloro(dioxoethylene-O,O'-)tellurate (AS 101)
|4.||Integrin alpha4beta1 (VLA-4)
|5.||3- (2- (4- azidobenzamidino)ethyl)- 5- hydroxyindole (SABA)
|6.||Transforming Growth Factor beta (TGF-beta)
|8.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|9.||Intercellular Signaling Peptides and Proteins (Growth Factors)
|1.||Drug Therapy (Chemotherapy)